Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival.
作者信息
Bachy Emmanuel, Cerhan James R, Salles Gilles
机构信息
Department of Hematology, Lyon Sud Hospital, Lyon France.
Lyon 1 Claude Bernard University, Lyon, France; and.
出版信息
Blood Adv. 2021 Mar 23;5(6):1729-1732. doi: 10.1182/bloodadvances.2020003797.
Abstract
摘要
相似文献
1
Early progression of disease in follicular lymphoma is a robust correlate but not a surrogate for overall survival.滤泡性淋巴瘤的早期疾病进展是一个有力的相关因素，但并非总生存的替代指标。
Blood Adv. 2021 Mar 23;5(6):1729-1732. doi: 10.1182/bloodadvances.2020003797.
2
Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.利妥昔单抗维持治疗可改善滤泡性淋巴瘤患者的总生存期——个体患者数据荟萃分析
Eur J Cancer. 2017 May;76:216-225. doi: 10.1016/j.ejca.2017.01.021. Epub 2017 Mar 21.
3
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.基于基因表达谱的滤泡性淋巴瘤患者预后预测评分：三队列回顾性训练和验证分析。
Lancet Oncol. 2018 Apr;19(4):549-561. doi: 10.1016/S1470-2045(18)30102-5. Epub 2018 Feb 20.
4
Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy.血液中的绝对 B 细胞计数可预测未经化疗而接受利妥昔单抗治疗的滤泡性淋巴瘤患者的长期反应。
Ann Hematol. 2020 Oct;99(10):2357-2366. doi: 10.1007/s00277-020-04208-x. Epub 2020 Aug 17.
5
A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients.FASL基因多态性与滤泡性淋巴瘤患者对利妥昔单抗的反应相关。
Am J Hematol. 2016 Jun;91(6):E305-7. doi: 10.1002/ajh.24354. Epub 2016 Apr 24.
6
Comment on "Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial".关于“利妥昔单抗维持治疗初治缓解的侵袭性B细胞淋巴瘤患者：随机NHL13试验结果”的评论
Haematologica. 2015 Nov;100(11):e480-1. doi: 10.3324/haematol.2015.133223.
7
[Prognostic Significance of Follicular Lymphoma International Prognostic Index 2 (FLIPI2) in Follicular Lymphoma Patients Treated with Rituximab Maintenance].利妥昔单抗维持治疗的滤泡性淋巴瘤患者中滤泡性淋巴瘤国际预后指数2（FLIPI2）的预后意义
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Apr;25(2):426-430. doi: 10.7534/j.issn.1009-2137.2017.02.021.
8
Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH-PRO-05 study.利妥昔单抗、干扰素-α-2b和剂量密集型CVP方案对国际预后指数（FLIPI）≥2的滤泡性淋巴瘤患者疗效显著。LNH-PRO-05研究的最终结果
Br J Haematol. 2019 Jul;186(1):168-170. doi: 10.1111/bjh.15760. Epub 2019 Jan 17.
9
Response to comment by P. Vassilakopoulos and colleagues.对P. 瓦西拉科普洛斯及其同事评论的回应。
Haematologica. 2015 Nov;100(11):e482. doi: 10.3324/haematol.2015.134288.
10
Randomized controlled trials in relapsed/refractory follicular lymphoma: a systematic review and meta-analysis.复发/难治性滤泡性淋巴瘤的随机对照试验：一项系统评价和荟萃分析。
J Oncol Pharm Pract. 2016 Oct;22(5):666-78. doi: 10.1177/1078155215603230. Epub 2015 Aug 28.
引用本文的文献
1
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma.一种基于机器学习的预测滤泡性淋巴瘤中POD24的模型：中国滤泡性淋巴瘤研讨会的一项研究
Biomark Res. 2025 Jan 3;13(1):2. doi: 10.1186/s40364-024-00716-4.
2
Combining Total Metabolic Tumor Volume With Beta-2-Microglobulin Levels Predicts Outcomes in High-Burden Follicular Lymphoma Patients.将总代谢肿瘤体积与β2-微球蛋白水平相结合可预测高负荷滤泡性淋巴瘤患者的预后。
Hematol Oncol. 2025 Jan;43(1):e70010. doi: 10.1002/hon.70010.
3
Surrogate endpoints in mature B-cell neoplasms - meaningful or misleading?成熟B细胞肿瘤中的替代终点——有意义还是有误导性？
Leukemia. 2025 Jan;39(1):25-28. doi: 10.1038/s41375-024-02483-5. Epub 2024 Dec 10.
4
Time for an individualized approach to first-line management of follicular lymphoma.是时候采用个体化方法来进行滤泡性淋巴瘤的一线治疗了。
Haematologica. 2022 Jan 1;107(1):7-18. doi: 10.3324/haematol.2021.278766.
5
Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation.一线滤泡性淋巴瘤的 III 期临床试验：设计与解读综述。
Adv Ther. 2021 Jul;38(7):3489-3505. doi: 10.1007/s12325-021-01738-2. Epub 2021 May 26.
本文引用的文献
1
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.滤泡性淋巴瘤GALLIUM研究中早期疾病进展与极低生存率的关联：奥妥珠单抗在降低早期进展率方面的益处
Haematologica. 2020 May;105(5):1465. doi: 10.3324/haematol.2020.246991.
2
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.利妥昔单抗维持治疗滤泡性淋巴瘤患者的无进展生存获益持续存在：PRIMA 研究的长期结果。
J Clin Oncol. 2019 Nov 1;37(31):2815-2824. doi: 10.1200/JCO.19.01073. Epub 2019 Jul 24.
3
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).一线弥漫性大 B 细胞淋巴瘤中无进展生存期作为总生存期替代终点的个体患者水平分析（SEAL）。
J Clin Oncol. 2018 Sep 1;36(25):2593-2602. doi: 10.1200/JCO.2018.77.9124. Epub 2018 Jul 5.
4
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.初治滤泡性淋巴瘤采用免疫化疗治疗的简化评分系统。
Blood. 2018 Jul 5;132(1):49-58. doi: 10.1182/blood-2017-11-816405. Epub 2018 Apr 17.
5
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.一线滤泡性淋巴瘤治疗中 30 个月完全缓解作为替代终点：多个随机试验的个体患者水平分析。
J Clin Oncol. 2017 Feb 10;35(5):552-560. doi: 10.1200/JCO.2016.70.8651. Epub 2016 Dec 28.
6
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.利妥昔单抗联合环磷酰胺、阿霉素、长春新碱和泼尼松治疗后滤泡性淋巴瘤的早期复发预示患者死亡风险高：一项来自国家淋巴瘤关爱研究的分析
J Clin Oncol. 2015 Aug 10;33(23):2516-22. doi: 10.1200/JCO.2014.59.7534. Epub 2015 Jun 29.
7
Surrogate endpoints in clinical trials: definition and operational criteria.临床试验中的替代终点：定义与操作标准。
Stat Med. 1989 Apr;8(4):431-40. doi: 10.1002/sim.4780080407.
Zotero 插件